查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999490

長效避孕藥市場：依產品類型、作用持續時間、最終用戶和通路分類－2026-2032年全球市場預測

Long-acting Contraception Market by Product Type, Duration Of Action, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，長效避孕藥市場價值將達到 39.4 億美元，到 2026 年將成長至 42.1 億美元，到 2032 年將達到 64.1 億美元，複合年成長率為 7.21%。

主要市場統計數據
基準年 2025 39.4億美元
預計年份：2026年 42.1億美元
預測年份 2032 64.1億美元
複合年成長率 (%) 7.21%

全面概述長效避孕技術、取得趨勢以及影響臨床和商業決策的相關人員需求。

在臨床療效、患者依從性優勢以及不斷變化的政策優先事項的驅動下，長效避孕技術已成為全球生殖健康策略的核心。本文說明了目前植入、注射避孕器和子宮內避孕器不僅是臨床選擇，更是減少意外懷孕和增強生育自主權的重要手段。除了技術進步之外，本文還探討了服務模式的轉變、報銷壓力和患者期望等因素，以闡明這些因素如何影響臨床和零售環境中長效避孕技術的推廣應用。

技術進步、服務交付創新以及不斷變化的監管和報銷重點如何重塑部署路徑和競爭需求。

在技​​術創新、醫療體系變革和社會政治因素的共同推動下，長效避孕領域正在迅速變化。從結構改良的植入式避孕器、耐受性更佳的皮下注射，到新一代荷爾蒙避孕器，植入層面的改善正與數位化醫療工具結合，從而簡化病患教育、知情同意和後續追蹤流程。同時，醫療服務提供者也不斷改進實踐，強調分工、臨床環境下的植入技術，以及將計劃生育服務整合到更廣泛的基層醫療工作流程中，這些都促進了長效避孕的普及。

評估 2025 年關稅變化如何重塑整個製造和採購生態系統的籌資策略、價格形成動態和供應韌性。

進口關稅和改變貿易流向的政策措施對製造商和醫療保健系統的產品供應、採購成本和策略採購決策產生了顯著影響。 2025年美國徵收的關稅累積效應，增加了從受影響地區進口零件和成品的成本，從而給製造、分銷和採購管道帶來了新的營運壓力。這促使許多製造商重新評估其企業發展區域，加快關鍵零件的在地採購，並調整商業合約價格，以在保障利潤率的同時，維持其對產品供應的承諾。

將產品設計、臨床交付環境和分銷管道聯繫起來的詳細細分分析揭示了價值、獲取和採用之間的交集。

細分市場分析揭示了每種產品類型、終端用戶通路和通路的不同績效促進因素和商業性重點。就產品類型而言，植入以其持續療效而著稱，但其植入和取出需要經過密集的臨床培訓。在植入中，多桿系統和單桿系統之間的差異會影響醫療服務提供者的偏好、庫存需求和病患諮詢。對於注射藥物，必須考慮給藥環境和製劑特性。肌肉注射和皮下注射在低溫運輸需求、給藥便利性和使用者接受度方面有明顯差異。子宮內避孕器 (IUD) 呈現出兩極分化的趨勢，含銅子宮內避孕器吸引了尋求非荷爾蒙方案的用戶，而含激素子宮內避孕器則在出血情況和作用持續時間方面展開競爭。

區域比較分析顯示，美洲、歐洲、中東、非洲和亞太地區的監管複雜性、製造業投資和分銷策略有何不同。

在美洲、歐洲、中東和非洲以及亞太地區這三大主要區域，區域趨勢正在影響長效避孕藥的監管發展、生產選擇和分銷策略。在美洲，政策重點和支付機制各不相同，一些地區的公共項目與其他地區由私人支付方主導的途徑不盡相同，這影響著採購週期和商業合約方式。該地區的供應鏈中心正日益重視對本地生產的投資，以減少對跨洋運輸的依賴和關稅風險。同時，市場准入的成功取決於能否在實際應用中證明產品的安全性和成本效益。

以臨床證據、生產規模和策略通路夥伴關係關係為中心的企業策略如何決定競爭地位。

該領域的企業層面行動的特點是投資於臨床證據、生產規模和經銷夥伴關係。主要企業優先考慮醫療設備的漸進式改進，以提高患者耐受性並簡化插入和使用流程，同時透過上市後監測和可操作性研究累積證據。與契約製造和物流供應商建立策略合作夥伴關係正成為企業保護自身營運免受貿易中斷影響並縮短新配方和改良型醫療設備上市時間的核心競爭優勢。

製造商、支付方和醫療保健提供者應採取切實可行的策略重點，以確保供應彈性、擴大提供者能力並加快以患者為中心的醫療服務取得。

行業領導者必須採取果斷行動，使產品開發、商業性執行和准入改進工作與不斷變化的系統需求和患者期望保持一致。首先，他們必須優先考慮供應鏈多元化和緊急時應對計畫，包括將關鍵零件近岸外包並建立替代性契約製造關係，以降低對特定供應商所在地的依賴以及關稅波動的影響。其次，計劃生育診所、專科醫療機構和醫院應投資於臨床教育計畫和工作共享計劃，以降低推廣應用的門檻並提升醫療服務提供者的能力。

透過高度透明和檢驗的研究設計來保證方法論的嚴謹性，該設計結合了對臨床醫生和採購負責人的初步訪談、監管證據和三角驗證的二手資訊。

本分析所依據的研究透過系統性地回顧同儕審查的臨床文獻、監管文件、政策文件以及一手定性數據，建構了可靠的證據基礎。一手研究包括對計劃生育診所、專科診所和醫院系統的臨床醫生進行結構化訪談，以及與採購經理、分銷合作夥伴和醫療設備製造商進行對話，以檢驗營運假設。二手資訊提供了醫療設備發展、監管先例和公共採購機制的歷史背景，並與一手證詞進行交叉核對，以確保一致性並減少偏見。

結論強調需要協調產品、供應和交付策略，以擴大可及性並實現臨床和商業性價值。

總之，長效避孕技術正處於臨床創新與複雜商業性化實施的十字路口。持續進展取決於各方協調努力，將醫療設備的研發與切實可行的交付模式、穩健的生產體係以及以患者為中心的參與策略相結合。在未來的發展中，能夠展現臨床價值、確保策略供應鏈並根據當地醫療保健系統的實際情況調整分銷方式的機構將更具優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 長效避孕藥市場：依產品類型分類

  • 植入
    • 多桿式植入
    • 單桿植入
  • 注射藥物
    • 肌肉內注射
    • 皮下注射
  • 避孕器
    • 銅子宮內避孕器
    • 含激素子宮內避孕器

第9章 依作用時間分類的長效避孕藥市場

  • 短期 LAC（1-3 個月）
  • 中期LAC（3-6個月）
  • 長期 LAC（1-5 年）

第10章 長效避孕藥市場：依最終用戶分類

  • 診所
    • 計劃生育診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院

第11章 長效避孕藥市場：依通路分類

  • 醫院藥房
  • 線上
    • 企業網站
    • 第三方平台
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章 長效避孕藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 長效避孕藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 長效避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國長效避孕藥市場

第16章：中國長效避孕藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Bayer AG
  • Cipla Limited
  • CooperCompanies, Inc.
  • Gedeon Richter Plc
  • HLL Lifecare Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Organon & Co.
  • Pfizer Inc.
  • Pregna International Ltd.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • SMB Corporation Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Theramex Ltd.
  • Viatris Inc
Product Code: MRR-563BF1FD02BB

The Long-acting Contraception Market was valued at USD 3.94 billion in 2025 and is projected to grow to USD 4.21 billion in 2026, with a CAGR of 7.21%, reaching USD 6.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.94 billion
Estimated Year [2026] USD 4.21 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 7.21%

A comprehensive orientation to long-acting contraceptive technologies, access dynamics, and stakeholder imperatives shaping clinical and commercial decisions

Long-acting contraceptive technologies have become central to reproductive health strategies worldwide, driven by clinical efficacy, patient adherence advantages, and evolving policy priorities. This introduction situates the reader within the contemporary landscape where implants, injectables, and intrauterine devices are not only clinical options but also levers for reducing unintended pregnancy and enhancing reproductive autonomy. The discussion frames technological evolution alongside changing delivery models, reimbursement pressures, and patient expectations that together shape adoption pathways across clinical and retail settings.

Transitioning from clinical evidence to market execution requires attention to manufacturing agility, regulatory alignment, and distribution nuances. Innovations in implant design, injectable formulations, and intrauterine device materials have reduced barriers to uptake, yet access disparities persist due to supply chain fragmentation and heterogeneous provider capabilities. The introduction underscores the imperative for stakeholders to appreciate both clinical differentiators and commercial realities when planning product launches, scaling distribution, or forming public-private partnerships that expand access and ensure sustained supply continuity.

How technological advances, service delivery innovation, and evolving regulatory and reimbursement priorities are reshaping adoption pathways and competitive imperatives

The landscape of long-acting contraception is shifting rapidly under the influence of technological innovation, health-system transformation, and socio-political forces. Device-level improvements-ranging from refined implant architectures and subcutaneous injectables with enhanced tolerability to next-generation hormonal intrauterine options-are converging with digital health tools that streamline patient education, consent, and follow-up. These developments are complemented by evolving provider practices that emphasize task-sharing, point-of-care insertion competencies, and integrated family planning services within broader primary care workflows.

Concurrently, regulatory environments and reimbursement frameworks are adapting to prioritize access, safety surveillance, and real-world evidence generation. Telehealth and e-commerce channels are expanding touchpoints for counseling and product procurement, while supply chain optimization efforts, such as regional manufacturing and strategic inventory management, aim to reduce lead times and price volatility. Together, these transformative shifts are redefining competitive imperatives: product differentiation must now pair clinical advantage with proven distribution strategies, cost efficiency, and patient-centered engagement models to achieve durable adoption.

Assessment of how 2025 tariff changes have reconfigured sourcing strategies, pricing dynamics, and supply resilience across manufacturing and procurement ecosystems

Policy actions that alter import duties and trade flows have a measurable impact on the availability, procurement costs, and strategic sourcing decisions for manufacturers and health systems. The cumulative impact of tariffs introduced in 2025 in the United States has created new operational pressures across manufacturing, distribution, and procurement channels by increasing landed costs for components and finished devices imported from affected geographies. This has led many manufacturers to reassess geographic footprints, accelerate localization of critical components, and reprice commercial contracts to preserve margin while maintaining access commitments.

In response, healthcare purchasers and public buyers have emphasized supplier diversification and multi-sourcing strategies to mitigate tariff exposure. Likewise, manufacturers with vertically integrated capabilities or regional production assets have gained strategic latitude to reallocate inventory and stabilize supply lines. Importantly, these tariff-driven dynamics have intensified conversations about long-term supply resilience, the strategic value of nearshoring, and the need for contractual clauses that transparently allocate cost risk. For clinical programs and non-profit distributors that operate on constrained budgets, the tariffs have prompted renegotiations, procurement prioritization, and closer coordination with manufacturers to ensure treatment continuity and equitable access.

In-depth segmentation intelligence linking product design, clinical delivery settings, and distribution channels to reveal where value, access, and adoption intersect

Segment-level analysis reveals differentiated performance drivers and commercial priorities across product types, end-user channels, and distribution pathways. Based on product type, implants distinguish themselves through sustained efficacy and require focused clinical training for insertion and removal; within implants, the distinctions between multi-rod and single-rod systems influence provider preference, inventory requirements, and patient counseling. Injectables require attention to administration setting and formulation profile; intramuscular versus subcutaneous formats have distinct cold-chain considerations, ease of administration, and acceptability among users. Intrauterine devices present bifurcated dynamics where copper IUDs attract users seeking non-hormonal options while hormonal IUDs compete on bleeding profile and duration of action.

Based on end user, clinics and hospitals exhibit different procurement behaviors and service models. Family planning clinics prioritize cost-effective, high-throughput solutions and community outreach integration, whereas specialty clinics may emphasize advanced counseling and differentiated device portfolios. Private hospitals balance patient expectations and premium services with efficiency, while public hospitals operate under budgetary constraints and broader population health mandates. Based on distribution channel, hospital pharmacies remain central for inpatient and surgical settings; online channels-including company websites and third-party platforms-offer expanded counseling and discreet procurement options; and retail pharmacies, both chain and independent, provide accessible points of care and opportunities for pharmacist-led education. Integrating these segmentation lenses clarifies where clinical value, provider training, reimbursement design, and patient engagement must align to translate product attributes into sustained uptake and equitable access.

Comparative regional analysis showing how regulatory complexity, manufacturing investment, and channel strategies differ across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape regulatory trajectories, manufacturing choices, and channel strategies for long-acting contraception across three macro areas: the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, policy priorities and payer mechanisms vary from public programs in some jurisdictions to private payer-dominated access pathways in others, which influences procurement cadence and commercial contracting approaches. Supply chain nodes in the region are increasingly targeted for local production investments to reduce dependence on transoceanic shipping and tariff exposure, while market access success hinges on demonstration of real-world safety and cost-effectiveness.

In Europe Middle East & Africa, regulatory harmonization efforts coexist with diverse national reimbursement landscapes and infrastructure disparities. This requires adaptive market entry strategies that combine centralized regulatory filings where possible with tailored country-level engagement for public health purchasers and non-governmental providers. Capacity-building initiatives and donor-funded programs often shape demand in lower-resource settings across the region, necessitating affordable, robust devices and simplified service delivery models. In Asia-Pacific, demographic trends, varied health system maturity, and growing domestic manufacturing capabilities create both scale opportunities and competitive intensity. Regional strategies here emphasize cost-efficient production, partnerships with local distributors, and digital-first approaches to patient education and telehealth-enabled counseling. Across all regions, stakeholders must reconcile clinical innovation with pragmatic deployment pathways to ensure sustained access and equitable outcomes.

How corporate strategies centered on clinical evidence, manufacturing scale, and strategic channel partnerships are determining competitive positioning

Company-level behavior in this sector is defined by investments in clinical evidence, manufacturing scale, and distribution partnerships. Leading firms are prioritizing incremental device improvements that enhance patient tolerability and simplify insertion or administration while simultaneously building evidence through post-market surveillance and pragmatic studies. Strategic alliances with contract manufacturers and logistics providers have emerged as a core competency for firms that want to shield operations from trade disruptions and achieve faster time-to-market for new formulations or device variants.

Competition is also playing out through commercial partnerships with clinic networks, hospital systems, and pharmacy chains to secure preferential procurement agreements and integrated training programs for providers. Smaller, specialized entrants are differentiating through niche product design, targeted end-user education, and agile direct-to-consumer engagement via online channels. Meanwhile, larger incumbents leverage broad regulatory expertise to expedite approvals across multiple jurisdictions. Across the competitive landscape, companies that can couple technical innovation with scalable manufacturing, robust clinician training programs, and transparent supply commitments will preserve commercial advantages and deliver predictable access for health systems and patients.

Practical strategic priorities for manufacturers, payers, and providers to secure supply resilience, expand provider capacity, and accelerate patient-centered access

Industry leaders should act decisively to align product development, commercial execution, and access initiatives with evolving system requirements and patient expectations. First, prioritize supply chain diversification and contingency planning that reduce exposure to concentrated supplier nodes and tariff volatility, including nearshoring critical components and establishing backup contract manufacturing relationships. Next, invest in clinical education programs and task-sharing initiatives that reduce insertion barriers and expand provider capacity in family planning clinics, specialty settings, and hospitals alike.

Additionally, firms should harness digital channels to expand counseling and follow-up care, integrating telehealth touchpoints with in-person services to improve adherence and satisfaction. Pricing strategies must be constructed with transparency and flexibility to support public sector procurement while preserving sustainable margins for private sales. Finally, cultivate partnerships with health systems, non-profit organizations, and payers to co-create demonstration programs that generate pragmatic evidence and support reimbursement dialogues. Through these measures, companies can accelerate adoption, secure supply resilience, and expand equitable access while maintaining commercial viability.

Transparent and verifiable research design combining primary clinician and procurement interviews, regulatory evidence, and triangulated secondary sources to ensure methodological rigor

The research underpinning this analysis combined systematic review of peer-reviewed clinical literature, regulatory filings, policy documentation, and primary qualitative inputs to construct a robust evidence base. Primary research included structured interviews with clinicians across family planning clinics, specialty practices, and hospital systems, as well as conversations with procurement leaders, distribution partners, and device manufacturers to validate operational assumptions. Secondary sources provided historical context on device development, regulatory precedents, and public procurement mechanisms, and were triangulated against primary testimony to ensure consistency and reduce bias.

Analytical approaches included cross-segment synthesis to connect product attributes with end-user requirements and channel characteristics, and scenario analysis to explore risk exposures such as trade policy shifts and supply interruptions. Quality assurance processes involved double-coding of interview transcripts, independent methodological review, and sensitivity checks on qualitative inferences. Wherever possible, findings emphasize verifiable clinical endpoints, documented regulatory milestones, and observable procurement behaviors rather than speculative projections, ensuring that conclusions are grounded in replicable evidence and practitioner insights.

Concluding synthesis emphasizing the necessity of coordinated product, supply, and delivery strategies to expand access and realize clinical and commercial value

In conclusion, long-acting contraceptive technologies sit at the intersection of clinical innovation and complex commercial execution. Sustained progress will depend on coordinated efforts that align device development with pragmatic delivery models, resilient manufacturing footprints, and patient-centered engagement strategies. The trajectory ahead favors organizations that can simultaneously demonstrate clinical value, secure strategic supply arrangements, and adapt distribution approaches to local health system realities.

Stakeholders should view the current environment as an opportunity to invest in durable capabilities: robust post-market evidence generation, provider training and task-sharing programs, and partnerships that bridge commercial and public health priorities. By doing so, manufacturers, payers, and providers can expand access, improve health outcomes, and create differentiated, sustainable value propositions across diverse clinical and geographic settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Contraception Market, by Product Type

  • 8.1. Implant
    • 8.1.1. Multi-Rod Implant
    • 8.1.2. Single-Rod Implant
  • 8.2. Injectable
    • 8.2.1. Intramuscular Injectable
    • 8.2.2. Subcutaneous Injectable
  • 8.3. Intrauterine Device
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD

9. Long-acting Contraception Market, by Duration Of Action

  • 9.1. Short-term LAC (1-3 months)
  • 9.2. Medium-term LAC (3-6 months)
  • 9.3. Long-term LAC (1-5 years)

10. Long-acting Contraception Market, by End User

  • 10.1. Clinics
    • 10.1.1. Family Planning Clinic
    • 10.1.2. Specialty Clinic
  • 10.2. Hospitals
    • 10.2.1. Private Hospital
    • 10.2.2. Public Hospital

11. Long-acting Contraception Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online
    • 11.2.1. Company Website
    • 11.2.2. Third-Party Platform
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Long-acting Contraception Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Long-acting Contraception Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Long-acting Contraception Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Long-acting Contraception Market

16. China Long-acting Contraception Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Afaxys, Inc.
  • 17.7. Agile Therapeutics, Inc.
  • 17.8. Bayer AG
  • 17.9. Cipla Limited
  • 17.10. CooperCompanies, Inc.
  • 17.11. Gedeon Richter Plc
  • 17.12. HLL Lifecare Ltd.
  • 17.13. Incepta Pharmaceuticals Ltd.
  • 17.14. Lupin Limited
  • 17.15. Mayne Pharma Group Limited
  • 17.16. Merck & Co., Inc.
  • 17.17. Organon & Co.
  • 17.18. Pfizer Inc.
  • 17.19. Pregna International Ltd.
  • 17.20. Shanghai Dahua Pharmaceutical Co., Ltd.
  • 17.21. SMB Corporation Pvt. Ltd.
  • 17.22. Sun Pharmaceutical Industries Ltd
  • 17.23. Teva Pharmaceutical Industries Ltd
  • 17.24. Theramex Ltd.
  • 17.25. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 201. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 237. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 249. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)